Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Acta cir. bras ; 34(2): e201900201, 2019. graf
Artículo en Inglés | LILACS | ID: biblio-989059

RESUMEN

Abstract Purpose: To investigated the effects of ginsenoside Rb1 on diabetic retinopathy in streptozotocin-induced diabetic rats. Methods: Diabetes was induced by a single intraperitoneal injection of streptozotocin (80 mg/kg) in male Wistar rats. Ginsenoside Rb1 (20, 40 mg/kg) was injected (i.p.) once a day for 4 weeks. Then, using fundus photography, the diameter and vascular permeability of retinal vessels were investigated. Retinal histopathology was undertaken. Contents of malondialdehyde (MDA) and glutathione (GSH) in retinas were assayed. Levels of nuclear factor erythroid 2-related factor 2 (Nrf2), glutathione cysteine ligase catalytic subunit (GCLC), and glutathione cysteine ligase modulatory subunit (GCLM) were measured. Results: Treatment with ginsenoside Rb1 attenuated the diabetes-induced increase in the diameter of retinal blood vessels. Ginsenoside Rb1 reduced extravasation of Evans Blue dye from retinal blood vessels. Ginsenoside Rb1 partially inhibited the increase in MDA content and decrease in GSH level in rat retinas. Nrf2 levels in the nuclei of retinal cells and expression of GCLC and GCLM were increased significantly in rats treated with ginsenoside Rb1. Conclusion: These findings suggest that ginsenoside Rb1 can attenuate diabetic retinopathy by regulating the antioxidative function in rat retinas.


Asunto(s)
Animales , Masculino , Ratas , Diabetes Mellitus Experimental/tratamiento farmacológico , Retinopatía Diabética/tratamiento farmacológico , Vasos Retinianos/efectos de los fármacos , Vasos Retinianos/patología , Ratas Wistar , Estreptozocina , Ginsenósidos/uso terapéutico
2.
Indian J Ophthalmol ; 2011 Jan; 59(1): 51-53
Artículo en Inglés | IMSEAR | ID: sea-136139

RESUMEN

A 48-year-old man presented following an episode of sudden onset simultaneous inferior altitudinal visual loss in his left eye and visual obscuration with shimmering in the inferonasal quadrant of the right eye. Clinical examination demonstrated left superior hemiretinal artery occlusion and an area of focal dynamic spasm along the right superior temporal branch retinal artery, the arteriolar spastic cycle was about 2 sec in duration. Hematological (including complete blood count, thrombophilia screen, vasculitic screen and serum magnesium), carotid, and cardiac investigations were normal. He was given acetazolamide 500 mg orally, timolol maleate 0.5% eye drops once daily and sublingual amyl-nitrate 0.8 mg, and maintained on felodipine 10 mg/day and aspirin 100 mg/day. The area of focal arteriolar spasm in the right eye resolved over two months. To our knowledge there are no prior reports of photographically documented dynamic focal retinal vascular spasm on a MEDLINE and PUBMED search.


Asunto(s)
Arteriolas/efectos de los fármacos , Arteriolas/patología , Esquema de Medicación , Estudios de Seguimiento , Fondo de Ojo , Humanos , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/complicaciones , Trastornos Migrañosos/fisiopatología , Fotograbar , Oclusión de la Arteria Retiniana/etiología , Oclusión de la Arteria Retiniana/patología , Vasos Retinianos/efectos de los fármacos , Vasos Retinianos/patología , Vasoconstricción/efectos de los fármacos , Vasodilatadores/administración & dosificación
3.
Yonsei Medical Journal ; : 325-327, 2007.
Artículo en Inglés | WPRIM | ID: wpr-22294

RESUMEN

Photodynamic therapy (PDT) involves the induction of endothelial cell death or occlusion of blood vessels. On the basis of this mechanism of action, PDT is used in the treatment of predominant classic choroidal neovascularization (CNV), if the classic component is over 50%, and in myopic CNV. This study describes 2 cases of distinctive, abnormal, large, subretinal new vessels that are thought to have originated from the choroids. Diminishment of the new vessels was observed following treatment with PDT.


Asunto(s)
Persona de Mediana Edad , Masculino , Humanos , Femenino , Vasos Retinianos/efectos de los fármacos , Enfermedades de la Retina/tratamiento farmacológico , Fotoquimioterapia , Neovascularización Patológica/tratamiento farmacológico , Angiografía
4.
Arq. bras. oftalmol ; 69(6): 941-944, nov.-dez. 2006. ilus
Artículo en Portugués | LILACS | ID: lil-440438

RESUMEN

Relato de caso de um paciente com telangiectasia justafoveal idiopática (TJI) tipo 1A, no olho direito, submetido a 4 mg de triancinolona intravítrea. O resultado foi avaliado por meio da acuidade visual e da tomografia de coerência óptica. A acuidade visual e a espessura retiniana macular medida na tomografia de coerência óptica, antes da injeção intravítrea de triancinolona, foram respectivamente de 20/100 e 569 æm e, após três semanas do tratamento foram de 20/60 e 371 æm e na sexta semana de 20/100 e 614 æm. A estabilização da parede vascular obtida com injeção intravítrea de triancinolona proporciona melhora transitória da visão e do edema macular em olhos com TJI-1A. Não foi demonstrada nenhuma ajuda permanente à fotocoagulação prévia.


Case report of one idiopathic juxtafoveal telangiectasis (IJT) 1A patient whose right eye was treated with a 4 mg intravitreal triamcinolone acetonide injection. The outcome was evaluated by visual acuity and optic coherence tomography. The visual acuity and the caliper retinal thickness before triamcinolone injection were respectively 20/100 and 569 æm, and 20/60 and 371 æm after three weeks and 20/100 and 614 æm after six week of follow-up. The stabilization of the vascular wall due to the intravitreal triamcinolone injection leads to a transitory improvement in vision and reduction in macular edema in the TJI 1A eyes. No permanent help by the photocoagulation could be shown.


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Glucocorticoides/administración & dosificación , Enfermedades de la Retina/tratamiento farmacológico , Vasos Retinianos/efectos de los fármacos , Telangiectasia/terapia , Triamcinolona Acetonida/administración & dosificación , Inyecciones , Edema Macular/tratamiento farmacológico , Vasos Retinianos/patología , Factores de Tiempo , Agudeza Visual , Cuerpo Vítreo/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA